Pathobiology of acute lymphoblastic leukemia

Seminars in Diagnostic Pathology

Volumn 28, Issue 2, 2011, Pages 124-134

  Paolini, Stefania ^a   Gazzola, Anna ^a   Sabattini, Elena ^a   Bacci, Francesco ^a   Pileri, Stefano ^a   Piccaluga, Pier Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukemia; BCR ABL1; NOTCH1; Targeted therapy; WHO classification

Indexed keywords

7 HYDROXYSTAUROSPORINE; ABELSON KINASE; ABELSON KINASE 1; ARSENIC TRIOXIDE; AURORA KINASE INHIBITOR; AVAGACESTAT; BAFETINIB; BCR ABL PROTEIN; BCR ABL1 PROTEIN; BLINATUMOMAB; BOSUTINIB; CYCLOPAMINE; DANUSERTIB; DASATINIB; EPRATUZUMAB; GAMMA SECRETASE INHIBITOR; IMATINIB; NELARABINE; NILOTINIB; NOTCH1 RECEPTOR; PROTEIN LMO1; PROTEIN LMO2; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; TEMSIROLIMUS; TOZASERTIB; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CLASSIFICATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ELDERLY CARE; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOPHENOTYPING; LEUKEMOGENESIS; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUMERICAL CHROMOSOME ABERRATION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL CHROMOSOME ABERRATION;

ANTINEOPLASTIC AGENTS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 79957994799     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.02.008     Document Type: Article

References (120)

1. Borowitz M., Chan J., et al. B lymphoblastic leukaemia/lymphomanot otherwise specified. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008, 168-170. IARC, Lyon. S. Swerdlow (Ed.).
2. Borowitz M., Chan J., et al. B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008, 171-175. IARC, Lyon. S. Swerdlow (Ed.).
3. Borowitz M., Chan J., et al. T lymphoblastic leukaemia/lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008, 176-178. IARC, Lyon. S. Swerdlow (Ed.).
4. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
5. Bassan R., Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011, 29:532-543.
6. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
7. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Practice 2006, 3:448-457.
8. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535-1548.
9. Armstrong S.A., Look A.T. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005, 23:6306-6315.
10. Ferrando A.A., Neuberg D.S., Staunton J., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.
11. Wang J.C., Dick J.E. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005, 15:494-501.
12. Pui C.H., Campana D., Evans W.E. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol 2001, 2:597-607.
13. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-615.
14. Basso G., Veltroni M., Valsecchi M.G., et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009, 27:5168-5174.
15. van der Velden V.H., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
16. Ahlbom A., Day N., Feychting M., et al. A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer 2000, 83:692-698.
17. Buffler P.A., Kwan M.L., Reynolds P., et al. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest 2005, 23:60-75.
18. Lanciotti M., Dufour C., Corral L., et al. Genetic polymorphism of NAD(P)H: quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 2005, 19:214-216.
19. Krajinovic M., Labuda D., Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002, 12:655-658.
20. Skibola C.F., Smith M.T., Kane E., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999, 96:12810-12815.
21. Skibola C.F., Smith M.T., Hubbard A., et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002, 99:3786-3791.
22. Healy J., Belanger H., Beaulieu P., et al. Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood 2007, 109:683-692.
23. Gast A., Bermejo J.L., Flohr T., et al. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia 2007, 21:320-325.
24. Biondi A., Cimino G., Pieters R., et al. Biological and therapeutic aspects of infant leukemia. Blood 2000, 96:24-33.
25. Pui C.H., Relling M.V. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000, 109:13-23.
26. Yeoh E.J., Ross M.E., Shurtleff S.A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
27. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002, 30:41-47.
28. Ferrando A.A., Armstrong S.A., Neuberg D.S., et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003, 102:262-268.
29. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
30. Harvey R.C., Mullighan C.G., Wang X., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
31. Hock H., Meade E., Medeiros S., et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004, 18:2336-2341.
32. Okuda T., van Deursen J., Hiebert S.W., et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330.
33. Wang Q., Stacy T., Binder M., et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996, 93:3444-3449.
34. Hong D., Gupta R., Ancliff P., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319:336-339.
35. Harrison C.J., Haas O., Harbott J., et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br J Haematol 2010, 151:132-142.
36. Harewood L., Robinson H., Harris R., et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003, 17:547-553.
37. Radich J.P. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol/Oncol Clin North Am 2001, 15:21-36.
38. Hoelzer D., Gökbuget N. Treatment of elderly patients with acute lymphoblastic leukemia. 2005 Educational Book 2005, 533-539. ASCO, Alexandria, VA, 41st Annual Meeting, May 13-17.
39. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukemias. Science 1960, 14:97.
40. Piccaluga P.P., Paolini S., Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007, 110:1178-1186.
41. Teitell M.A., Pandolfi P.P. Molecular genetics of acute lymphoblastic leukemia. Annu Review Pathol 2009, 4:175-198.
42. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev 2005, 5:172-183.
43. Gruber F., Mustjoki S., Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 2009, 145:581-597.
44. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev 2007, 7:823-833.
45. Meyer C., Schneider B., Reichel M., et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 2005, 102:449-454.
46. Barabe F., Kennedy J.A., Hope K.J., et al. Modeling the initiation and progression of human acute leukemia in mice. Science 2007, 316:600-604.
47. Armstrong S.A., Kung A.L., Mabon M.E., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003, 3:173-183.
48. O'Neil J., Look A.T. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 2007, 26:6838-6849.
49. Piccaluga P.P., Malagola M., Rondoni M., et al. Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leuk Lymphoma 2006, 47:469-472.
50. Pui C.H., Raimondi S.C., Hancock M.L., et al. Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. J Clin Oncol 1994, 12:2601-2606.
51. Kager L., Lion T., Attarbaschi A., et al. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica 2007, 92:1561-1564.
52. Foa R., Vitale A., Mancini M., et al. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br J Haematol 2003, 120:484-487.
53. Chapiro E., Russell L., Radford-Weiss I., et al. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 2006, 108:3560-3563.
54. Akasaka T., Balasas T., Russell L.J., et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007, 109:3451-3461.
55. Russell L.J., Akasaka T., Majid A., et al. t(6;14)(p22;q32): a new recurrent IGH translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111:387-391.
56. Russell L.J., Capasso M., Vater I., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
57. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
58. Russell L.J., De Castro D.G., Griffiths M., et al. A novel translocation, t(14;19)(q32;p13), involving IGH and the cytokine receptor for erythropoietin. Leukemia 2009, 23:614-617.
59. Yoda A., Yoda Y., Chiaretti S., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010, 107:252-257.
60. Hertzberg L., Vendramini E., Ganmore I., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
61. Chapiro E., Russell L., Lainey E., et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24:642-645.
62. Cario G., Zimmermann M., Romey R., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
63. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
64. Grimaldi J.C., Meeker T.C. The t: (5; 14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 1989, 73:2081-2085.
65. De Keersmaecker K., Marynen P., Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica 2005, 90:1116-1127.
66. Moorman A.V., Richards S.M., Martineau M., et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003, 102:2756-2762.
67. Harrison C.J., Moorman A.V., Broadfield Z.J., et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004, 125:552-559.
68. Nachman J.B., Heerema N.A., Sather H., et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007, 110:1112-1115.
69. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
70. Iacobucci I., Storlazzi C.T., Cilloni D., et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009, 114:2159-2167.
71. Kuiper R.P., Schoenmakers E.F., van Reijmersdal S.V., et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007, 21:1258-1266.
72. Den Boer M.L., van Slegtenhorst M., De Menezes R.X., et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009, 10:125-134.
73. Puil L., Liu J., Gish G., et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994, 13:764-773.
74. Tauchi T., Boswell H.S., Leibowitz D., et al. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 1994, 179:167-175.
75. Kharas M.G., Fruman D.A. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005, 65:2047-2053.
76. Konopka J.B., Watanabe S.M., Witte O.N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984, 37:1035-1042.
77. Piccaluga P.P., Rondoni M., Paolini S., et al. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther 2007, 7:1597-1611.
78. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
79. Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965-1971.
80. Piccaluga P.P., Malagola M., Amabile M., et al. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica 2004, 89:1269-1271.
81. Thomas D.A., Faderl S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396-4407.
82. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460-466.
83. Yanada M., Takeuchi J., Sugiura I., et al. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008, 93:287-290.
84. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
85. Wassmann B., Pfeifer H., Goekbuget N., et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006, 108:1469-1477.
86. Delannoy A., Delabesse E., Lheritier V., et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006, 20:1526-1532.
87. de Labarthe A., Rousselot P., Huguet-Rigal F., et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007, 109:1408-1413.
88. Ottmann O.G., Wassmann B., Pfeifer H., et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109:2068-2076.
89. Vignetti M., Fazi P., Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood 2007, 109:3676-3678.
90. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
91. La Rosee P., Deininger M.W. Resistance to imatinib: mutations and beyond. Semin Hematol 2010, 47:335-343.
92. Hofmann W.K., Komor M., Hoelzer D., et al. Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004, 45:655-660.
93. von Bubnoff N., Peschel C., Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003, 17:829-838.
94. Pfeifer H., Wassmann B., Pavlova A., et al. Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) developing resistance to imatinib. Blood 2005, 106:147.
95. Soverini S., Vitale A., Poerio A., et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 29 December 2010, epub ahead of print.
96. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
97. Ottmann O., Dombret H., Martinelli G., et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110:2309-2315.
98. Piccaluga P.P., Rosti G., Rondoni M., et al. Dasatinib (sprycel®) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or lymphoid blast phase chronic myeloid leukemia after imatinib failure: a single-center experience. Hematol J 2007, 92:PO351.
99. Porkka K., Koskenvesa P., Lundan T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008, 112:1005-1012.
100. Ottmann O.G., Larson R.A., Kantarjian H.M., et al. Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib. Blood 2007, 110:2815.
101. Gambacorti-Passerini C., Cortes J., Kantarjian H., et al. Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with Philadelphia chromosome positive leukemias. Haematologica 2008, 93:2. (Abstract 0403).
102. Foa R., Fazi P., Vitale A., et al. Dasatinib monotherapy as 1st line treatment of Ph acute lymphoblastic leukemia (ALL) patients: update of the GIMEMA LAL1205 study. Haematologica 2008, 93:367. (Abstract 0992).
103. Ravandi F., O'Brien S., Thomas D., et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010, 116:2070-2077.
104. Soverini S., Martinelli G., Colarossi S., et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006, 24:e51-e52.
105. Heerema N.A., Harbott J., Galimberti S., et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 2004, 18:693-702.
106. Primo D., Tabernero M.D., Perez J.J., et al. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 2005, 19:713-720.
107. Mullighan C.G., Miller C.B., Radtke I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
108. Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002, 2:103-112.
109. Mullighan C.G., Su X., Zhang J., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
110. Kirstetter P., Thomas M., Dierich A., et al. Ikaros is critical for B cell differentiation and function. Eur J Immunol 2002, 32:720-730.
111. Martinelli G., Iacobucci I., Papayannidis C., et al. New targets for Ph+ leukaemia therapy. Best Pract Res Clin Haematol 2009, 22:445-454.
112. Lin T.L., Wang Q.H., Brown P., et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS ONE 2010, 5:e15262.
113. Bargou R., Leo E., Zugmaier G., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
114. Piccaluga P.P., Arpinati M., Candoni A., et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2010, 52:325-327.
115. Handgretinger R., Zugmaier G., Henze G., et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011, 25:181-184.
116. Weng A.P., Ferrando A.A., Lee W., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
117. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006, 20:2096-2109.
118. Ferrando A.A. The role of NOTCH1 signaling in T-ALL. Hematol Am Soc Hematol Educ Program 2009, 353-361.
119. Graux C., Cools J., Melotte C., et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084-1089.
120. Agostinelli C., Paterson J.C., Gupta R., et al. Detection of LMO2 in normal human tissues and haematopoietic and non-haematopoietic tumours by a newly developed rabbit monoclonal antibody. Blood 2009, 114:2942. Abstract.